Roche’s stock has moved up 7.7% in the last twelve months compared with industry’s gain of 24.7%. <\/p>\n
The company reports results under two divisions: Pharmaceuticals and Diagnostics. All growth rates mentioned below are on a year-over-year basis and at constant exchange rates. <\/p>\n
Sales in 2017 came in at CHF 53.3 billion, up 5%. Earnings per share came in at CHF 15.34 in 2017, up from CHF 14.53 in 2016.\u00a0 Sales at the Pharmaceuticals division increased 5% driven by strong growth in Tecentriq, Ocrevus, Alecensa and Perjeta. Diagnostics division sales climbed 5% primarily on the back of strong immunodiagnostic business. <\/p>\n
Results in Detail <\/p>\n
Herceptin sales improved 3% due to increasing demand in the United States and Brazil. Perjeta sales grew 19% following increased demand in the neoadjuvant and metastatic settings. Sales of Kadcyla (+10%) were driven by increasing demand in the international markets. <\/p>\n
Meanwhile, sales of Avastin decreased due to increasing use of cancer immunotherapy medicines in lung cancer. <\/p>\n
Sales of Rituxan\/MabThera (1%) were driven by growth in the immunology segments. Growth in Gazyva\/Gazyvaro (41%) was strong despite increasing competition in chronic lymphocytic leukemia. <\/p>\n
Recently launched drugs, Tecentriq and Alecensa for lung cancer are off to a strong start. Tecentriq, Ocrevus and Alecensa contributed CHF1.4 billion of new sales. <\/p>\n
Performance of the immunology franchise was driven by increased sales of Actemra\/RoActemra (14%), and strong uptake of Esbriet (13%) and Xolair (16%). Increasing use of Actemra\/RoActemra in the subcutaneous formulation drove sales. <\/p>\n
However, sales of Tarceva declined (18%) due to growing use of other therapeutic options. Sales of Xeloda (10%) continue to be hit by generic competition. Sales of Tamiflu also declined 33%. <\/p>\n
Revenues at the Diagnostics division climbed 5% on the back of solid performance of the Centralised and Point of Care Solutions (7%) unit, which was in turn, propelled by Immunodiagnostics (13%). Tissue Diagnostics (13%) and Molecular Diagnostics (11%) also performed impressively. <\/p>\n
However, Diabetes Care sales declined 4% as sales continue to be impacted by challenging market conditions, particularly in North America. <\/p>\n
2018 Outlook <\/p>\n
Roche now expect sales to remain stable or grow in low-single digits. The company expects core earnings to grow in high-single digits. The company intends to further increase its dividend in 2017 in local currency. <\/p>\n
Story Continues <\/p>\n
Pipeline Progress <\/p>\n
The company won FDA approvals for two new drugs in 2017 \u2014 Ocrevus for the treatment of relapsing and primary progressive forms of multiple sclerosis and Hemlibra for haemophlia A with factor VIII inhibitors. <\/p>\n
The company continues to expand the label for its existing drugs \u2014 Perjeta for adjuvant (after surgery) treatment of HER2-positive early breast cancer at high risk of recurrence, in combination with Herceptin and chemotherapy as well as full approval of Perjeta for neoadjuvant use. <\/p>\n
During the fourth quarter, Roche obtained FDA approval of a label expansion of a few drugs \u2014Alecensa for first-line treatment in ALK-positive non-small cell lung cancer (“NSCLC”), Zelboraf in Erdheim-Chester disease, Gazyva for untreated advanced follicular lymphoma and Avastin for glioblastoma in adult patients whose cancer has progressed after prior treatment. <\/p>\n
Alecensa was also approved as a monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive, advanced NSCLC in Europe. In January 2018, EMA approved Ocrevus for the treatment of both the relapsing and the primary progressive forms of multiple sclerosis and Hemlibra was granted a positive opinion by the CHMP. <\/p>\n
Meanwhile, Tecentriq in combination with Avastin showed positive study results in lung cancer and kidney cancer. <\/p>\n
On the diagnostics front, Roche entered into a strategic, long-term partnership with GE Healthcare to jointly develop and co-market digital clinical decision support solutions. <\/p>\n
Our Take <\/p>\n
Roche performance in 2017 was strong driven by contribution from newly launched drugs. The label expansion of key drugs, Perjeta, Tecentriq and Alecensa will further drive growth. Ocrevus and Hemlibra have been successfully launched. However, sales of Avastin and Tarceva continue to decline. <\/p>\n
Approval of new drugs and a potential label expansion of existing drugs bode well for Roche as its legacy drugs like Herceptin, MabThera are facing competition from biosimilars. <\/p>\n
Novartis AG NVS has already launched its biosimilar version of Rituxan\/ MabThera in Europe. Amgen AMGN also obtained FDA approval for a biosimilar version of Avastin for treatment of five types of cancers including lung cancer, colorectal cancer, glioblastoma, renal cell carcinoma and cervix cancer. <\/p>\n
Zacks Rank & Key Pick <\/p>\n
Roche carries a Zacks Rank #3 (Hold). <\/p>\n
A better-ranked stock in the healthcare sector is Exelixis EXEL with a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.. <\/p>\n
Exelixis’ earnings per share estimates have moved up from 72 cents to 77 cents for 2018 over the last 60 days. The company delivered a positive earnings surprise in the last four quarters, with an average beat of 572.92%. <\/p>\n
Wall Street’s Next Amazon <\/p>\n
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius. <\/p>\n
Click for details >> <\/p>\n
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report<\/a>
\u00a0
Roche Holding AG (RHHBY) : Free Stock Analysis Report<\/a>
\u00a0
Novartis AG (NVS) : Free Stock Analysis Report<\/a>
\u00a0
Amgen Inc. (AMGN) : Free Stock Analysis Report<\/a>
\u00a0
Exelixis, Inc. (EXEL) : Free Stock Analysis Report<\/a>
\u00a0
To read this article on Zacks.com click here.<\/a>
\u00a0
Zacks Investment Research<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"Roche Holding AG’s RHHBY reported sales of CHF13.8 billion in the fourth quarter of 2017, up 5% from…\n","protected":false},"author":2,"featured_media":93484,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[159,114,166,39,167,160,161,168,162,163,169,170,171,172,173,174,134,175,164,165,176,177,178,179],"class_list":["post-93483","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-401k","tag-business","tag-business-news","tag-economy","tag-finance","tag-financial-information","tag-investing","tag-investment-tools","tag-investor","tag-market-news","tag-mortgage","tag-mutual-funds","tag-personal-finance","tag-quote","tag-real-estate","tag-retirement","tag-roche","tag-stock","tag-stock-research","tag-stock-valuation","tag-stocks","tag-suze-orman","tag-tax","tag-track-portfolio"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116826676053554821","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/93483","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=93483"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/93483\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/93484"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=93483"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=93483"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=93483"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}